Success Metrics

Clinical Success Rate
98.6%

Based on 70 completed trials

Completion Rate
99%(70/71)
Active Trials
87(45%)
Results Posted
61%(43 trials)
Terminated
1(1%)

Phase Distribution

Ph phase_1
29
15%
Ph phase_4
34
17%
Ph not_applicable
8
4%
Ph phase_2
59
30%
Ph early_phase_1
4
2%
Ph phase_3
43
22%

Phase Distribution

33

Early Stage

59

Mid Stage

77

Late Stage

Phase Distribution177 total trials
Early Phase 1First-in-human
4(2.3%)
Phase 1Safety & dosage
29(16.4%)
Phase 2Efficacy & side effects
59(33.3%)
Phase 3Large-scale testing
43(24.3%)
Phase 4Post-market surveillance
34(19.2%)
N/ANon-phased studies
8(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.6%

70 of 74 finished

Non-Completion Rate

5.4%

4 ended early

Currently Active

87

trials recruiting

Total Trials

195

all time

Status Distribution
Active(121)
Completed(70)
Terminated(4)

Detailed Status

Completed70
Recruiting63
Not yet recruiting33
Active, not recruiting24
Withdrawn3
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
195
Active
87
Success Rate
98.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.3%)
Phase 129 (16.4%)
Phase 259 (33.3%)
Phase 343 (24.3%)
Phase 434 (19.2%)
N/A8 (4.5%)

Trials by Status

active_not_recruiting2412%
completed7036%
enrolling_by_invitation11%
recruiting6332%
terminated11%
not_yet_recruiting3317%
withdrawn32%

Recent Activity

Clinical Trials (195)

Showing 20 of 195 trialsScroll for more
NCT07046819Phase 2

Tirzepatide in MetALD

Recruiting
NCT07734870Phase 2

Tirzepatide for Treatment of CCCA

Not Yet Recruiting
NCT07463846Phase 1

A Study to Evaluate ALN-2232 in Participants With Obesity

Recruiting
NCT06965413Phase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Active Not Recruiting
NCT06651177Phase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
NCT07527910Phase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Recruiting
NCT07756359Phase 4

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

Not Yet Recruiting
NCT06439277Phase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Recruiting
NCT06937099Phase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Recruiting
NCT06143956Phase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
NCT07165028Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Recruiting
NCT06937086Phase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Recruiting
NCT07747805Phase 2

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

Not Yet Recruiting
NCT06162715Phase 2

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Active Not Recruiting
NCT07738276Phase 3

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Not Yet Recruiting
NCT07573163Phase 2

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Recruiting
NCT07734792Phase 2

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

Not Yet Recruiting
NCT07191873Phase 4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Not Yet Recruiting
NCT07559500Phase 1

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Recruiting
NCT07349641Phase 2

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
195